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Abstract
Background: Detection of cardiac rejection is a major problem in cardiac transplantation. The gold standard is, and remains, endo-
myocardial biopsy. Purpose: Evaluation of MR-imaging and MR-spectroscopy for detection of cardiac rejection. Methods: Orthotopic
cardiac transplantation (HTX) was performed in 13 pigs (body weight 30 kg). All animals obtained immunosuppressive (triple) therapy for
1 week after the operation. Thereafter immunosuppression was stopped to induce cardiac rejection. MRI and MRS (1.5 Tesla General
Electrics Signa) were performed pre- and post-operatively on days 10, 17, 24 and 31. The degree of rejection was determined post-
operatively using endomyocardial biopsy (Texas grading score). Results: (1) MR-imaging: LV function remained unchanged after HTX.
LV mass increased (+42%; P , 0.05) with cardiac rejection. (2) MR-spectroscopy: a marked reduction in the ratio of phosphocreatine and
adenosine triphosphate, respectively, to inorganic phosphate was observed in the rejecting hearts. (3) Histologic grading confirmed cardiac
rejection after stopping immunosuppression. The Texas score was 5.7 – 0.8 at autopsy. Conclusions: MR-imaging and MR-spectroscopy
allow the detection of changes associated with cardiac rejection. Both techniques are correlated with histologic rejection. However,
endomyocardial biopsy remains the gold standard for reliable detection of cardiac rejection. Ó 1998 Elsevier Science B.V. All rights
reserved
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1. Introduction
Rejection episodes constitute the major problems after
heart transplantation; moreover differentiation between
rejection and infection may be difficult [1,2]. So far, only
endomyocardial biopsy with histological evaluation has
been established for accurate diagnosis of rejection [3].
Several non-invasive methods have been investigated and
some of them are currently used in clinical trials [1,4–10].
However, until now, no method has been accepted to
replace endomyocardial biopsy.
Like other groups, we have been able to demonstrate
some significant correlations between phosphorous MR-
spectroscopy (MRS) and the severity of histologic rejection
[11–19]. The main finding consists of a reduction of PCr/Pi
and/or bATP/Pi by MRS with a concomitant increase in
wall thickness, ventricular muscle mass and increased T2
relaxation time by MR-imaging (MRI) [20,21]. However, to
our knowledge, no other groups have used the combination
of MR-imaging and MR-spectroscopy to diagnose acute
rejection. The aim of the present investigation was the con-
secutive assessment of both MR-imaging and MR-spectro-
scopy changes before and after orthotopic cardiac
transplantation with and without immunosuppression.
2. Methods
Orthotopic cardiac transplantation was performed in
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anesthetized (balanced narcosis) pigs (30 kg). Donors
and recipients were not from the same litter but were
blood typed and size matched. In addition a blood donor
from the same litter as the recipient was necessary to pre-
vent post-operative anaemia. The mean cold ischemic time
was 26 min and the aortic crossclamp time 68 min. Car-
diopulmonary bypass was conducted at high flow rate
(.100 ml/kg per min) in mild hypothermia after aortic
and bicaval cannulation. Animals were kept intubated dur-
ing the first night after transplantation and treated under
ICU conditions for 3 days to improve monitoring. Echo-
cardiography assessment was repeated several times dur-
ing the early post-operative period. Animals received
immunosuppression starting at the day of transplantation,
and including a triple therapy (cyclosporine with serum
trough levels around 200–250 ng/ml, azathioprin and pre-
dnisolon). One week post-operatively, immunosuppression
was tapered in order to provoke cardiac rejection. All ani-
mals were kept according to the European Convention on
Animal Care. Thirteen animals were operated on, of
which six survived more than 10 days and one up to 31
days.
2.1. MR examinations
MR-imaging and MR-spectroscopy examinations were
repeatedly performed under general anesthesia before and
after heart transplantation on days 10, 17, 24, and 31 using a
1.5 Tesla whole body scanner (Signa, General Electrics,
USA) with a dual tuned flexible surface coil (Medical
Advances, USA). Pre-operatively the donor heart was
examined.
2.2. MR-imaging
A gradient echo sequence (16 phases) was used in a long
(four chamber view) and short axis view to assess LV
dimensions and cardiac function at end-diastole and end-
systole. ECG-triggering was carried out to reduce motion
artefacts. From these measurements, left ventricular septal
and posterior wall thickness, left ventricular short and long
axes, left ventricular volume (area length method) and left
ventricular muscle mass were calculated. Mass was deter-
mined from the outer LV volume minus the intracavitary
volume calculated by the area length method. Additionally,
T2 relaxation time was calculated in the septal region at
signal intensities of echo time 30 and echo time 90 ms,
respectively.
2.3. MR-spectroscopy
31P phosphorous spectra were obtained with a 2D-CSI
pulse sequence, 16 · 16 voxels, abadiatic pulse, relaxation
time 2 s. Signals were obtained from the apical part of the
left ventricle including some blood within the left ventricle.
Acquisition time was 17 min. The following parameters
were calculated using conjugated gradient fitting routines:
2,3-diphospho-glycerol (2,3 DPG), inorganic phosphate
(Pi), phosphocreatine (PCr) and adenosine triphosphate (g,
a, b ATP) (Fig. 1). Since no absolute values were obtained,
PCr/Pi, b-ATP/Pi and PCr/b-ATP ratios were determined
before and after heart transplantation.
2.4. Histologic assessment of rejection
Myocardial biopsy specimens were obtained pre-opera-
tively from endomyocardial biopsies of the right ventricle,
post-operatively during MR examinations and, at the con-
clusion of the study, from autopsy samples of the right and
left ventricle. The grade of rejection was classified accord-
ing to the Texas grading system (semi-quantitative score
from 0–10).
2.5. Statistics
Data are expressed as the mean – SD. Correlations were
calculated using a regression analysis. P-Values smaller
than 0.05 were considered to be significant. Pre- and post-
operative data were compared either with a non-parametric
Mann–Whitney Rank-Sum test or the paired t-test using
Stata 5.0, Stata Santa Monica, CA.
3. Results
Six animals survived beyond day 10, three survived up
to post-operative day 17 and one to 31 days after trans-
plantation. Endomyocardial biopsies showed mild rejec-
tion during the first week post-operatively, while animals
were still immunosuppressed (Texas grade 0–2, mean:
0.5 – 0.9). Subsequent histologic evaluation revealed
moderate to severe rejection with a significant increase in
the Texas grade to 4–6, mean: 5.7 – 0.8 at autopsy
(P , 0.05).
3.1. Baseline hemodynamics (Table 1)
Heart rate increased significantly after heart transplanta-
tion, whereas mean arterial and pulmonary pressures did not
change significantly.
3.2. MR-imaging (Table 1)
Septal and posterior wall thickness, as well as muscle
mass, showed a significant increase after transplantation
when compared to pre-operative values (baseline: 8.6 –
0.5 and 7.2 – 1.8 mm, and at conclusion of the study:
12.6 – 1.9 and 10.9 – 2.0 mm, respectively; P , 0.05).
Left ventricular mass increased from 43 – 16 g at baseline
to 74 – 13 g at the end of the study (P , 0.05). T2-relaxa-
tion time of the lateral and septal wall increased from 47 – 6
at baseline to 50 – 6 at the end of the study.
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3.3. MR-spectroscopy (Table 2 and Fig. 1)
The PCr/Pi ratio decreased from 9.8 – 3.4 to 4.0 – 0.9 at
the conclusion of the study. Similarly the bATP/Pi ratio
decreased from 4.4 – 1.7 at baseline to 1.6 – 0.8 during
rejection (P , 0.05); on the other hand PCr/bATP
remained essentially unchanged.
3.4. Correlations between MRI and MRS data,
respectively, and histologic rejection (Table 3)
Muscle mass, septal wall thickness, stroke volume, inor-
ganic phosphate, T2-relaxation time and ejection fraction
show a significant correlation with the histologic grade of
rejection (P , 0.05).
4. Discussion
Non-invasive detection of cardiac rejection is still a sub-
ject of intensive research. Various methods have been used
experimentally and clinically for detection of acute rejec-
tion after cardiac transplantation. So far no reliable para-
meter has been found, although several methods such as
electrocardiography, echocardiography, blood serum tests,
and nuclear scintigraphy have been used [1,4–10]. Like-
wise, the role of magnetic resonance imaging and spectro-
scopy remains unclear, although these techniques have been
evaluated both experimentally and clinically for diagnosis
of cardiac rejection [11–21].
4.1. MR-imaging for detection of rejection
The MRI criteria for assessing myocardial rejection are
similar to those used for echocardiography. Changes like an
increase in wall thickness or muscle mass have been
reported but were not found to be sensitive enough to detect
rejection [4,15,20,21]. The increase in mass has been ex-
plained by myocardial edema. A prolongation of T2-relaxa-
tion time of the interventricular septum has been reported
with rejection but has been found not to be sensitive enough
to prove, or rule out, cardiac rejection [21].
Table 1
Baseline hemodynamics and MRI data
Pre-operative Post-operative (>10 days) P-value
Baseline hemodynamics (n = 6)
Heart rate (beats/min.) 107 – 16 142 – 6 ,0.05
Mean arterial pressure (mmHg) 102 – 23 89 – 7 n.s.
Mean pulmonary artery pressure (mmHg) 17 – 5 20 – 6 n.s.
MRI data (n = 6)
Septal thickness (mm) 8.6 – 0.5 12.6 – 1.9 ,0.05
Posterior wall thickness (mm) 7.2 – 1.8 10.9 – 2.0 ,0.05
LV muscle mass (g) 43 – 16 74 – 13 ,0.05
T2-relaxation time (ms) 47 – 6 50 – 6 n.s.
Table 2
MRS data
Pre-operative Post-operative
(>10 days)
P-value
MRS data (n = 6)
Pi 10 – 9 25 – 12 ,0.05
PCr 98 – 34 99 – 25 n.s.
bATP 44 – 12 41 – 12 n.s.
PCr/bATP 2.2 – 0.3 2.4 – 0.3 n.s.
PCr/Pi 9.8 – 3.4 4.0 – 0.9 n.s.
bATP/Pi 4.4 – 1.7 1.6 – 0.8 ,0.05
Fig. 1. Phospohorous spectra of a heart (anteroseptal region) before (left)
and 24 days after transplantation (right). Peaks from left to right show 2,3
diphospho-glycerol (2,3 DPG), inorganic phosphate (Pi), phosphocreatine
(PCr), adenosine triphosphate (g, a, b ATP). The spectrum on the right
shows an increase in inorganic phosphate (Pi) and a decrease in phospho-
creatine ATP values, respectively, when compared to the spectrum at
baseline. These data are compatible with acute myocardial rejection.
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These data are, however, not specific for detection of
cardiac rejection. Wall thickening has been reported after
myocardial cardioplegia, etc. An increase in wall thickness
or left ventricular muscle mass is relatively insensitive with
regard to cardiac rejection and represents usually a ‘late’
stage of cardiac rejection when myocardial edema is severe
and cardiac function depressed [1,14]. Therefore, these
parameters provide only limited information on rejection
and can be detected by MRI only when the process is
advanced with moderate to severe rejection.
4.2. MR-spectroscopy for detection of cardiac rejection
Severe biochemical changes of the cardiac cells are found
in the presence of myocardial rejection. Histologically two
different types of rejection have been described, namely a
vascular and a cellular rejection type. Biochemical changes
can however, only be detected when myocardial or intersti-
tial tissue is affected. Under these circumstances a reduction
in the energy-rich phosphates has been described with a
decrease in phosphocreatine and an increase in inorganic
phosphate [11–13]. Therefore, several authors have recom-
mended the use of magnetic resonance spectroscopy with a
decrease in the ratio of PCr to b-ATP or PCr/Pi as well as b-
ATP/Pi to detect changes associated with myocardial rejec-
tion [16–18].
In the present study a decrease in two of the three ratios
(PCr/Pi and b-ATP/Pi) was observed during acute rejec-
tion, whereas the third ratio PCr/b-ATP did not change
significantly. These data show that changes in the energy-
rich phosphates can be detected with MR-spectroscopy.
However, these ratios show relatively large variations
and, thus, are only of limited value for detection of rejec-
tion (Table 2). Previously, Bottomley et al. [18] reported
a sensitivity of 50% and a specificity of 73% for detec-
tion of cardiac rejection by MR-spectroscopy. These authors
followed 14 patients with MR-spectroscopy and used
each patient as its own control. These authors showed
clearly that sensitivity and specificity for detection of
cardiac rejection are probably low and provide only limi-
ted information for non-invasive detection of cardiac rejec-
tion.
Correlations between histologic rejection and MRI/MRS
(Table 3) showed significant regressions for muscle mass,
septal wall thickness, stroke volume, ejection fraction and
T2-relaxation time (MRI), inorganic phosphate (MRS) and
histologic rejection.
4.3. Limitations of MR assessment for cardiac rejection
(1) MR-imaging: dimensional data and T2 relaxation
times give only limited information on the histologic
changes of the myocardium associated with cardiac rejec-
tion. Similar data can be obtained with other imaging
modalities such as echocardiography or CT scanning.
Furthermore, the availability of MR-imaging systems is lim-
ited and the systems are costly.
(2) MR-spectroscopy: temporal and spatial resolution is
limited with the technique used (surface coil) and only api-
cal regions of the myocardium can be studied reliably. Con-
tamination by blood (cavity), motion artefacts and skeletal
muscle may be a major problem for MR-spectroscopy and
increase variability.
5. Conclusions
Detection of cardiac rejection is feasible with MR-ima-
ging and MR-spectroscopy although correlations with his-
tologic grading are low to moderate. Variability and
reproducibility of MR-spectroscopy for detection of cardiac
rejection are not yet defined and their clinical value for
assessing cardiac rejection remains to be confirmed.
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Appendix A Conference discussion
Dr A. Murday (London, UK): I think from the data that you have
presented there needs to be an extra control in there. There needs to be
a control of a pig having a transplant and being immunosuppressed
throughout, because although it is antilogical, it may be that your changes
are just due to the time after transplantation rather than rejection because
they are all rejecting.
Dr Walpoth: I think that is the reason why we have immunosuppressed
the animals for 1 week with cyclosporine levels, with the triple therapy,
like in patients. In all animals at the end of 1 week of treatment we have
had endomyocardial biopsy results. They showed that only in two animals
there is a Texas 2, which is a low rejection grade which would not be
treated in patients. It is only thereafter that we stopped immunosuppression
to allow the animals to go into rejection, where most of them showed
moderate rejection. So each animal serves as its own control.
Dr Murday: I appreciate that that control exists, but I still think that it is
just feasible that the changes you see in MRI could be argued to be just the
consequence of time. In other words, if you wait 4 weeks, you have the
MRI changes. It is not very likely, but it is possible.
Dr Walpoth: I do not think so, because what you are alluding to is the
change you would see during the operation, which is the transplant trauma,
the reperfusion of the ischemic heart which, of course, will induce some
changes, such as edema, very early after surgery. You can measure that
and several groups have shown that this is very transient, and that it is
reversed after a couple of days. That is why we elected to treat them for 1
week before stopping immunosuppression, so that they could serve as their
own control.
.
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